Alzheimer's disease (AD) is associated with the deposition of b-amyloid (Ab) plaques in the brain. In this issue, by cleverly processing patient samples, Lu et al. define a novel structural model of Ab fibrils from AD brain, revealing surprising differences from in vitro fibrils. These findings may lead to structure-specific inhibitors and more selective amyloid-imaging methods.
Alzheimer's disease (AD) is the most common neurodegenerative disorder, affecting 35 million people worldwide. This number is predicted to skyrocket with the aging ''baby boomer'' population. The pathological hallmark of AD is the presence of extracellular neuritic plaques comprised of b-amyloid (Ab) peptides, cleavage products of the amyloid precursor protein (APP), consisting of 39-43 residues. Hence, a detailed structural understanding of Ab aggregation in AD patients would greatly help the rational design of drugs. In this issue, Lu et al. present structural analyses of Ab fibers derived from patient brain samples; their analyses suggest new avenues for tailored diagnostics and therapies.
Accumulation of Ab in the brain is likely the cause of AD (Hardy and Selkoe, 2002) . Indeed, genetic mutations that cause familial AD enhance the production of Ab. These lesions include mutations in the APP gene, which result in a more amyloidogenic protein or in the presenilins (PS1 or PS2) that encode components of the gsecretase enzyme that processes APP to liberate Ab peptides. Current therapeutic strategies aim at targeting and eliminating Ab (Gandy and DeKosky, 2013) . However, this approach remains challenging as the precise nature of the most toxic Ab conformers (amyloid fibrils, oligomers of various sizes, and/or protofibrils) is unresolved. Moreover, because the course and neuropathology of AD can vary greatly, distinct Ab assemblies within the brain may lead to different clinical phenotypes.
Ab aggregates formed in vitro can show significant structural diversity (Petkova et al., 2005 ), yet structures of Ab aggregates in vivo have remained elusive. Are they similar to in vitro aggregates? Are they as polymorphic as aggregates formed in vitro, or does one conformation dominate at the expense of others within AD brains?
In this issue of Cell, Lu et al. (2013) attack this problem in an elegant way. Previous work showed that new Ab fibers formed in a reaction using short bits of pre-existing fibrils to act as seeds retain the structures of the starting seeds (Kodali et al., 2010; Petkova et al., 2005) . The authors therefore reasoned that amyloidcontaining material from brain tissue might seed in an in vitro fibril assembly reaction. The structures of the fibrils formed in these reactions would reflect those present in the brain and may provide quantities suitable for atomic-scale analyses.
The paper reports the use of a newly developed, enhanced amyloid extraction protocol to isolate seed material from the brain of two AD patients with distinct clinical histories. When this material was mixed with synthetic Ab40 peptide, long fibrils grew within a few hours, which could be examined using solid-state nuclear magnetic resonance (NMR). What came next was remarkable and completely unexpected.
In each of the two patients, the fibrils that grew out of a reaction seeded with amyloid-enriched brain extract adopted a single predominant structure, even when extracts from different brain regions from the same patient were used. However, the brain-seeded fibrils from the first and second patients differed markedly. Thus, it seems that each patient had developed structurally distinct fibrils in their brains, raising the intriguing possibility that structural differences in Ab aggregates reflect or perhaps underlie the differences in clinical history of these patients.
The authors then amplified enough brain-seeded Ab fibrils to perform highquality solid state NMR and generated a full structural model for Ab40 fibrils from the brain of the first patient. These studies revealed several exciting findings. Importantly, the in vivo structural model exhibited key differences from previously determined models for in vitro fibrils, including specific side-chain contacts and new solvent exposed and buried surfaces. The illumination of these structural insights offers a treasure trove for the structure-based design of antagonists of Ab aggregation.
Beyond therapeutic opportunities, these findings may also usher in a new generation of imaging modalities. Compounds that preferentially bind amyloid fibrils have been harnessed as positron emission tomography (PET) ligands, enabling in vivo imaging of amyloid deposition. These imaging agents are now a powerful tool in AD clinical research and diagnosis and serve as beacons for clinical trials of Ab-lowering therapeutics (Gandy and DeKosky, 2013) . The structural insights emerging from Lu et al. could lead to enhanced PET ligands specific for certain structures (Figure 1 ). The structures may also help clarify the mechanism of polythiophene-based fluorescent ''amyloidotropic'' dyes, which change colors upon binding to conformationally distinct aggregates (Sigurdson et al., 2007) .
Many important questions and opportunities lay ahead. The total brain plaque load is a notoriously poor predictor of cognitive fitness. Might distinct Ab morphologies show a better correlation with cognition? Expanding this study to large AD brain collections will not only illustrate the diversity and complexity of Ab aggregates but could help to define the prognosis of individuals at risk for AD. Are different morphologies selectively targeted by subsets of anti-Ab antibodies? If so, the limited success of current AD immunotherapy may be due, at least in part, to inadequate patient stratification, and personalized antibodies may be needed. Are there active mechanisms promoting ''benign'' Ab assemblies and are such mechanisms genetically encoded? If so, could small-molecule, peptide, or antibody-based therapeutic approaches be used to redirect Ab misfolding trajectories toward the more benign conformations? On the other hand, do genetic risk factors for AD, such as the ε4 allele of APOE, rare variants in TREM2, and others, enhance the formation of more disease-associated Ab assemblies?
Many neurodegenerative diseases including tau and Ab in AD, a-synuclein in Parkinson's disease, and SOD1 (and perhaps TDP-43 and FUS) in ALS, are caused by ''prionoids,'' protein aggregates that can propagate from one cell to another even if they are not transmissible between individuals (Aguzzi and Rajendran, 2009). Lu et al.'s findings support the view that Ab comes in discrete strains, as has been suggested for a-synuclein (Guo et al., 2013) and tau (Clavaguera et al., 2013) . However, a rigorous (and, we believe, necessary) test of this idea will require proof that each of the different conformers generates new seeds retaining the same phenotypic ''strainness'' across multiple generations, as is the case for prion diseases and all other infectious pathogens (Aguzzi and Polymenidou, 2004) .
Although exciting, the new findings should not be considered without some caveats. Although the structural data are consistent with each of the two AD brains harboring just one dominant Ab structure, that dominance may stem from conformational selection. That is, there may be a wealth of structures in AD brains with only few susceptible to amplification. Even if only one Ab structure was present at time of autopsy, did many other fibril structures coexist during disease progression with one winner emerging, which propagated throughout the brain? The structural approaches presented by Lu et al. are a great starting point and hopefully these studies will be extended to many more AD patient samples in order to define the full range of Ab structures that form in the brain during AD pathogenesis. Finally, these types of approaches may also provide insight into the molecular features responsible for prion-like templating and spreading of protein aggregates in AD, other neurodegenerative disorders, and possibly also systemic amyloidoses. Lu et al. (2013) analyzed Ab structures from two Alzheimer's disease patient brains, with different clinical histories. Both Alzheimer's disease patient's harbored extensive Ab pathology, but perhaps the Ab aggregates formed distinct morphologies during disease (e.g., morphology A and morphology B). The authors extracted amyloid-enriched material from brain and used this to seed in vitro Ab fibrillization reactions. Solid-state NMR was used to determine a structural model for the Ab aggregates from patient 1, revealing novel side-chain contacts, solvent-exposed and solvent-buried surfaces. These structural insights can be used to develop structure-specific radioligands for in vivo amyloid imaging, as well as more selective small molecule inhibitors and therapeutic antibodies. (B) An example of how Ab structural insights can be translated to the clinic. Different Alzheimer's disease patients likely harbor distinct Ab aggregate structures and thus some will respond better to certain treatments than other ones. New structure-specific PET radioligands based on insights from Lu et al. (2013) and future follow-up studies can be used for in vivo amyloid imaging to help stratify patients. Additional biomarkers (e.g., analytes from blood or cerebrospinal fluid [CSF] ) may also be utilized to help stratify Alzheimer's patients. Following patient stratification, structure-selective Ab inhibitors and therapeutic antibodies could be used to treat patients with specific Ab structures.
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